LSE · Stocky rates: Cautious

HERALD INVESTMENT TRUST PLC ORD (HRI.L)

p3,060.00 ▲ +0.82% as of 6 Aug, 06:52
49
/ 100
Neutral

What Stocky thinks

Cautious. Hengrui Pharmaceuticals scores well on value metrics (70/100) with reasonable multiples, but growth stalls at 39/100—indicating mature, slow-expansion pharma dynamics. Leadership alignment (62.5/100) is moderate; no founder-CEO anchor mitigates execution risk. The Vulnerable profile reflects structural exposure to China regulatory tightening and generic competition, eroding margin durability despite near-term valuation appeal.

Compounder Score
70/100
Business quality — profitability, growth, capital efficiency.
Leadership Alignment
63/100
Founder-led, insider ownership, capital allocation history.
Vulnerability
0/100
Downside resilience — customer concentration, supply chain, refinancing risk.
Value Score
70/100
Valuation vs peers and history — is this a good price to pay?

What Stocky gives investors that other tools don't

Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for HERALD INVESTMENT TRUST PLC ORD:

49
VERDICT

Stocky Verdict — one score, everything

Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 49/100, you know instantly whether to dig deeper or skip.

Rated
MOAT

Moat Score — is there a real edge?

Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.

63
LEADER

Leadership Alignment — is management on your side?

Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.

0
RISK

Vulnerability Profile — what could break?

Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.

Elite
TRACK

Track Record — does the system work?

Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.

24/7
ALERTS

Alerts + Portfolio insights

Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.

HERALD INVESTMENT TRUST PLC ORD (HRI.L) — frequently asked

Is HERALD INVESTMENT TRUST PLC ORD (HRI.L) a good investment right now?

Stocky rates HERALD INVESTMENT TRUST PLC ORD (HRI.L) at 49/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. Hengrui Pharmaceuticals scores well on value metrics (70/100) with reasonable multiples, but growth stalls at 39/100—indicating mature, slow-expansion pharma dynamics. Leadership alignment (62.5/100) is moderate; no founder-CEO an

What is HRI.L's Stocky Verdict?

HRI.L's current Stocky Verdict is 49/100, placing it in the "Cautious" band. This composite combines a 70/100 Compounder score, 63/100 Leadership, Moat rating, and analyst signal.

Does HERALD INVESTMENT TRUST PLC ORD have a competitive moat?

Stocky hasn't finalised a Moat Score for HERALD INVESTMENT TRUST PLC ORD yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.

Is HERALD INVESTMENT TRUST PLC ORD's leadership aligned with shareholders?

HERALD INVESTMENT TRUST PLC ORD scores 63/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.

What are the biggest risks to HRI.L?

HERALD INVESTMENT TRUST PLC ORD's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to HERALD INVESTMENT TRUST PLC ORD.

This is just the surface. See the whole picture on HERALD INVESTMENT TRUST PLC ORD.

Sign up free and unlock the full analysis on HRI.L — the same tools professional analysts use, personalised to your portfolio:

  • Every analyst covering HRI.L — full list with star ratings, price targets, historical hit-rate. Not just the top 3 you see above.
  • Full Vulnerability Profile — customer concentration, refinancing walls, stress-test scenarios (-20% revenue, +200bp rates) modelled specifically for HRI.L.
  • Bull & bear thesis — the AI-written counter-argument every retail investor forgets to read.
  • Portfolio fit check — how HRI.L changes your sector concentration, correlation and Verdict-weighted quality.
  • Ask Stocky AI — "What are the biggest 3-year risks to HRI.L?" · "Is HRI.L overvalued vs its 5-year median?" · unlimited follow-ups on your portfolio.
  • Live alerts — analyst target changes, insider buys, big moves — the day they happen.
Start free · 14 days Plus, no card →

Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.

STOCKY VERDICT
49
/ 100 · Neutral

Or jump straight to the interactive dashboard for HRI.L in the app.